Three independent studies have shown that an α-synuclein assay technology detected early Parkinson's with high levels of sensitivity and specificity.
Neurovascular Diagnostics intends to commercialize a test for unruptured intracranial aneurysm tests that use RNA expression signatures.
The Yale professor said that deep-learning algorithms could give digital pathology the push it needs for broader adoption.
The firm said that with its mimetope peptide assays, which measure the concentration of blood in a sample, patients would receive the right dose of the right drug.
The polygenic score snags a greater percentage of people at risk of early heart attack than current tests that rely on single-gene variants or blood chemistry.
The device consists of a reservoir that enables the analyte to contact only the top of a screen-printed electrode, increasing sensitivity.
Its CEO said that although a hospital screening test for sepsis is a focus, a fever test that informs about antibiotic use could be available sooner.
Quest will have a broader relationship with Cleveland Clinic in diagnostic development, the companies say.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
Having demonstrated their ATR-FTIR technique in mice, the researchers are moving to human samples and they plan to be in clinical trials in around two years.